Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients (iFRAIL)

May 12, 2025 updated by: The Cleveland Clinic
The objective of this study is to assess the feasibility and effectiveness of dedicated ambulator-assisted physical activity in lung transplant inpatients. The primary hypothesis is that an ambulator-assisted intervention for lung transplant patients will prove feasible and may result in improved frailty, hospital outcomes, including less need for inpatient rehabilitation and shorter length of stay in the hospital.

Study Overview

Detailed Description

Lung transplant is a lifesaving intervention for patients with advanced lung disease. In addition to this, patients can experience an improved quality of life and reduction in disability post transplant. Despite extensive candidate evaluation and pre-transplant scoring, waitlist mortality remains relatively high, in 2015 at 16.4 per 100 waitlist years and post-transplant 1-year mortality 16.6%.

Frailty is defined as a "generalized vulnerability to stressors" resulting from an accumulation of cognitive and physiologic deficits, which can lead to a significant decline in health following an additional stressor such, i.e. major surgery. Frailty has been associated with delayed graft function and mortality in kidney transplant recipients and waitlist mortality in liver transplant candidates. Components of frailty include weight loss, exhaustion (self-reported), weakness, slow walking speed and low physical activity, however all these components have a complex interplay.

In lung transplant, frailty was also found to be independently associated with patient-reported disability and with subsequent de-listing or death before transplant. There is conflicting evidence regarding the role of pre-transplant frailty on post-transplant outcomes in regards to overall post-operative mortality and hospital length of stay. However, prospective investigations have shown improvements in frailty following lung transplant can lead to improved disability over the first year following lung transplant.

Physical therapy interventions aimed at elderly, frail non-transplant population, were found to be successful at reducing future frailty and mobility related disability. Important components of these regimens include resistance and endurance building exercises to improve maximum oxygen consumption and muscular strength. Identifying at-risk candidates pre- and post-transplant may allow for interventions to improve outcomes. It may also assist in preventing re-admissions, since previous investigations have shown frailty was associated with 30-day hospital re-admissions in patients with after colorectal surgery.

Post-transplant, standard care should include physical activity for patients to help prevent post-operative atelectasis, increase energy, fuel appetite and reduce frailty. In lung transplant patients, exercise following transplantation has been shown to beneficial for muscular strength, six-minute walk distance and self-reported physical functioning. However the reality of care is that physical therapy availability may limit patients from ambulating more than once daily while hospitalized. An improvement in the level of activity available to patients is critical to daily their daily progress after transplant.

The investigators hypothesize that a graded protocol of ambulation which can be implemented by a dedicated patient care nursing assistant (PCNA) multiple times daily will provide significant benefit to patients without the labor and cost requirements of full-time nursing and physical therapy expertise.

The investigators believe this intervention will improve frailty in participants. These benefits will be objectively measured with evaluation of frailty during the pre- and post-transplant period, along with documentation of hospital length of stay, discharge disposition, overall mortality, 30-day readmission rate, and the number of inpatient falls.

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Inclusion Criteria (pre-transplant):

  1. Participant has personally signed and dated informed consent form indicating understanding of all pertinent aspects of the study.
  2. Speaks fluent English
  3. Active on the waiting list for a single or bilateral lung transplant
  4. Able to ambulate pre-transplant (not bed/wheelchair bound) with or without assistive device

Inclusion Criteria (post-transplant)

  1. Have undergone a single or bilateral lung transplant
  2. Admitted to the transplant floor (J82) after discharge from the ICU
  3. Complete history and physical examination on file
  4. Physical therapy consult ordered (standard of care) and JH-HLM Scale of greater than or equal to 6 within 72 hours of transfer to the transplant floor

Exclusion Criteria (pre-transplant):

  1. Age <18 years
  2. Admitted to hospital for expedited transplant work-up
  3. Admitted to hospital prior to date of transplant
  4. Current invasive mechanical ventilation or placement of ECMO cannula
  5. Multi-organ transplant patients (liver-lung, heart-lung)

Exclusion Criteria (post-transplant)

  1. Bed rest order placed
  2. Requiring invasive mechanical ventilation during the day/night

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ambulatory Intervention
Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
No Intervention: No Ambulator
Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospital Length of Stay
Time Frame: Through study completion, approximately 1 year post-transplant
The duration of time in days for the index admission for the patient beginning immediately after lung transplant
Through study completion, approximately 1 year post-transplant
Regular Nursing Floor Length of Stay
Time Frame: Through study completion, approximately 1 year post-transplant
The duration of time in days a patient stayed on the regular nursing floor following lung transplant
Through study completion, approximately 1 year post-transplant
30-day readmission
Time Frame: Up to 30 days following discharge
The incidence of readmission to hospital within 30 days of patient discharge from hospital after index lung transplant admission
Up to 30 days following discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in physical frailty phenotype
Time Frame: pre-transplant to 1 year following transplant
Change in physical frailty phenotype pre and post-transplant
pre-transplant to 1 year following transplant
Change in short physical performance battery
Time Frame: pre-transplant to 1 year following transplant
Change in short physical performance battery pre and post-transplant
pre-transplant to 1 year following transplant
Change in AMPAC/6-click score
Time Frame: pre-transplant to 1 year following transplant
Change in AMPAC/6-click score pre and post-transplant
pre-transplant to 1 year following transplant
Change in sarcopenia
Time Frame: pre-transplant to 1 year following transplant
Change in sarcopenia pre and post-transplant (m2)
pre-transplant to 1 year following transplant
Change in nutritional status; serum albumin
Time Frame: pre-transplant to 1 year following transplant
Change in nutritional status; serum albumin pre and post-transplant (g/dL)
pre-transplant to 1 year following transplant
Change in nutritional status; serum protein
Time Frame: pre-transplant to 1 year following transplant
Change in nutritional status; serum protein pre and post-transplant (g/dL)
pre-transplant to 1 year following transplant
Change in nutritional status; BMI
Time Frame: pre-transplant to 1 year following transplant
Change in nutritional status; BMI pre and post-transplant (kg/m2)
pre-transplant to 1 year following transplant
Change in eyeball frailty assessment
Time Frame: pre-transplant to 1 year following transplant
Change in eyeball frailty assessment pre and post-transplant
pre-transplant to 1 year following transplant
Presence of aspiration
Time Frame: pre-transplant to 1 year following transplant
Presence of aspiration pre and post-transplant
pre-transplant to 1 year following transplant
Readmission to ICU
Time Frame: Through study completion, approximately 1 year post-transplant
Readmission to ICU during index hospitalization for lung transplant
Through study completion, approximately 1 year post-transplant
In-hospital falls
Time Frame: Through study completion, approximately 1 year post-transplant
Clinical documentation of a fall during index hospital admission for lung transplant
Through study completion, approximately 1 year post-transplant
Aspiration event
Time Frame: Through study completion, approximately 1 year post-transplant
Presence of clinical aspiration event during index hospital admission for lung transplant
Through study completion, approximately 1 year post-transplant
Graft survival
Time Frame: Through study completion, approximately 1 year post-transplant
Duration of graft functioning from transplant until patient death or re-transplantation
Through study completion, approximately 1 year post-transplant
Accelerometer step change
Time Frame: pre-transplant (weeks to a year to more) and immediately after transplant, up to 1 year post-transplant
Change in steps from pre-transplant to post-transplant
pre-transplant (weeks to a year to more) and immediately after transplant, up to 1 year post-transplant
Accelerometer energy expenditure
Time Frame: pre-transplant (weeks to a year to more) and immediately after transplant, up to 1 year post-transplant
Change in energy expenditure from pre-transplant to post-transplant
pre-transplant (weeks to a year to more) and immediately after transplant, up to 1 year post-transplant
Accelerometer time ambulating
Time Frame: pre-transplant (weeks to a year to more) and immediately after transplant, up to 1 year post-transplant
Change in time ambulating from pre-transplant to post-transplant
pre-transplant (weeks to a year to more) and immediately after transplant, up to 1 year post-transplant

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marie Budev, DO, The Cleveland Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2018

Primary Completion (Actual)

April 15, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

August 13, 2018

First Submitted That Met QC Criteria

August 15, 2018

First Posted (Actual)

August 17, 2018

Study Record Updates

Last Update Posted (Actual)

May 14, 2025

Last Update Submitted That Met QC Criteria

May 12, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe